Husereau D - Search Results

1

Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment.

Beca J, Husereau D, Chan KKW, Hawkins N, Hoch JS. Beca J, et al. Among authors: husereau d. Pharmacoeconomics. 2018 Jan;36(1):7-15. doi: 10.1007/s40273-017-0583-4. Pharmacoeconomics. 2018. PMID: 29110141 Free article.

2

Guidelines for health technologies: specific guidance for oncology products in Canada.

Mittmann N, Evans WK, Rocchi A, Longo CJ, Au HJ, Husereau D, Leighl NB, Isogai PK, Krahn MD, Peacock S, Marshall D, Coyle D, Taylor SC, Jacobs P, Oh PI. Mittmann N, et al. Among authors: husereau d. Value Health. 2012 May;15(3):580-5. doi: 10.1016/j.jval.2011.12.006. Epub 2012 Feb 16. Value Health. 2012. PMID: 22583470 Free article.

3

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Husereau D, et al. Pharmacoeconomics. 2013 May;31(5):361-7. doi: 10.1007/s40273-013-0032-y. Pharmacoeconomics. 2013. PMID: 23529207 Free article.

4

Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?

Husereau D, Marshall DA, Levy AR, Peacock S, Hoch JS. Husereau D, et al. Int J Technol Assess Health Care. 2014 Apr;30(2):179-87. doi: 10.1017/S0266462314000142. Epub 2014 May 7. Int J Technol Assess Health Care. 2014. PMID: 24806420

5

Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs.

Husereau D, Dempster W, Blanchard A, Chambers J. Husereau D, et al. Value Health. 2014 Dec;17(8):888-94. doi: 10.1016/j.jval.2014.08.2673. Epub 2014 Nov 4. Value Health. 2014. PMID: 25498784 Free article.

6

Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration.

Husereau D, Drummond M, Petrou S, Greenberg D, Mauskopf J, Augustovski F, Briggs AH, Moher D, Loder E, Carswell C. Husereau D, et al. Pharmacoeconomics. 2015 May;33(5):535-6. doi: 10.1007/s40273-015-0277-8. Pharmacoeconomics. 2015. PMID: 25893576 No abstract available.

7

Using Phase-Based Costing of Real-World Data to Inform Decision-Analytic Models for Atrial Fibrillation.

Tawfik A, Wodchis WP, Pechlivanoglou P, Hoch J, Husereau D, Krahn M. Tawfik A, et al. Among authors: husereau d. Appl Health Econ Health Policy. 2016 Jun;14(3):313-22. doi: 10.1007/s40258-016-0229-2. Appl Health Econ Health Policy. 2016. PMID: 26924098

8

Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation.

Tawfik A, Bielecki JM, Krahn M, Dorian P, Hoch JS, Boon H, Husereau D, Pechlivanoglou P. Tawfik A, et al. Among authors: husereau d. Clin Pharmacol. 2016 Aug 11;8:93-107. doi: 10.2147/CPAA.S105165. eCollection 2016. Clin Pharmacol. 2016. PMID: 27570467 Free PMC article.

9

CHANGING HEALTH TECHNOLOGY ASSESSMENT PARADIGMS?

Husereau D, Henshall C, Sampietro-Colom L, Thomas S. Husereau D, et al. Int J Technol Assess Health Care. 2016 Jan;32(4):191-199. doi: 10.1017/S0266462316000386. Epub 2016 Oct 21. Int J Technol Assess Health Care. 2016. PMID: 27766998

10

Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA.

Kristensen FB, Husereau D, Huić M, Drummond M, Berger ML, Bond K, Augustovski F, Booth A, Bridges JFP, Grimshaw J, IJzerman MJ, Jonsson E, Ollendorf DA, Rüther A, Siebert U, Sharma J, Wailoo A. Kristensen FB, et al. Among authors: husereau d. Value Health. 2019 Jan;22(1):13-20. doi: 10.1016/j.jval.2018.08.010. Epub 2018 Dec 13. Value Health. 2019. PMID: 30661627 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

113 results

Search Page